BioInvest In The News

Five Prime: A Prime Play on Proteins (9-22-14)
U~T San Diego Isis Pharmaceuticals (9-3-14)
Dick Davis Investment Digest (7-23-14)
The Life Sciences Report (6-19-14)
Moneyshow - Three Favorites from a Biotech Expert (3-12-14)
Dick Davis Investment Digest (1-22-14)
Company Updates
Pharmacyclics Update (9-10-14)

Pharmacyclics Update (9-10-14)

Special Update – PCYC Scores VA Contract, PCYC Shares Still Undervalued – In breaking news, PCYC has been awarded a large Veterans Affairs (VA) contract for Imbruvica.   Details – VA – A Large Buying Group: The following information was posted today (dated September 4, 2014)   Solicitation Number: VA797P14R0033 Contract Award Date: September 4, [...]

Pharmacyclics Update (7-23-14)

Pharmacyclics Update (7-23-14)

SPECIAL UPDATE – PCYC – GILD Severely Restrictive Zydelig Label Underscores Imbruvica’s Superior Profile – Reiterate BUY – Gilead received approval midday for Zydelig (idelalisib) for three blood cancers – refractory CLL, indolent FL and SLL – some what ahead of the August/September PDUFA dates.  While the approvals were widely expected, the strict BLACK BOX [...]

Novavax Update (10-27-14)

Novavax Update (10-27-14)

BioInvest News for NVAX – Novavax Enters Ebola Vaccine Race with a Bang – After remaining mum during the recent Ebola hype-fest, NVAX waited until they had truly legitimate news to report.  This weekend, the company released positive preclinical Ebola vaccine data in guinea pigs at the 8th Vaccine and ISV Conference in Philadelphia (10/26). [...]